Sitravatinib plus Tislelizumab for Advanced Biliary Tract Cancer in Patients Whose Disease Did Not Respond to at Least 1 Systemic Therapy

March 2022, Vol 3, No 1

Given that monotherapy with immune checkpoint inhibitors, including the PD-1 inhibitor tislelizumab, has a modest effect in advanced biliary tract cancers, several combination strategies to improve the antitumor activity of immune checkpoint inhibitors are being explored.

Based on preclinical evidence that adding anti-angiogenic agents to immune checkpoint inhibitors induces antitumor immune responses, an open-label, phase 2 study is evaluating the safety and efficacy of the combination of tislelizumab plus the multitargeted angiogenic inhibitor sitravatinib in patients with advanced biliary tract cancer whose disease did not respond to at least 1 systemic therapy.

Do-Youn Oh, MD, PhD, Cancer Research Institute, Seoul National University College of Medicine, South Korea, described the study at the 2022 ASCO GI Cancers Symposium.

An exploratory objective is to assess the relationship between the combination’s efficacy and tumor biomarkers.

Key eligibility criteria include patients with histologically proved biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, and ampulla of Vater cancer, whose disease did not respond to at least 1 previous systemic chemotherapy; have not used ≥2 previous chemotherapy regimens; and have ECOG performance status of 0 or 1.

Patients who have previously received an immune checkpoint inhibitor are eligible to be enrolled. Patients who had unacceptable adverse events during previous immune checkpoint inhibitor treatment will be excluded.

Eligible patients will receive oral sitravatinib 120 mg once daily plus intravenous tislelizumab 200 mg once every 3 weeks until disease progression, unacceptable adverse events, or withdrawal of consent.

The study’s primary end point is disease control rate; secondary end points are overall response rate, progression-free survival, duration of response, overall survival, and EORTC QLQ-C30, overall adverse events, and immune-related adverse events.

For evaluating the metabolic response, the 18F-FDG PET/CT scan will be performed before treatment and at the first evaluation of response. Tissue biopsies will be conducted at screening, at the first response evaluation, and at disease progression.

The study is currently recruiting patients, with a planned enrollment of 43 patients. Overall, the cohort of patients who have not received a PD-1 or PD-L1 inhibitor will enroll 33 patients, and the cohort of those who have previously received a PD-1 or PD-L1 inhibitor will enroll 10 patients.

Source

Oh DY, Kim JW, Chon H, et al. Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: trial in progress. Abstract TPS490.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: